Trial · NCT01008475
Results by group22
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 22
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Safety Part: Number of Subjects Experiencing DLTs (Dose Limiting Toxicity) | Safety Part: EMD 525797 250 mg + SoC | 0 | subjects | ||
| Safety Part: Number of Subjects Experiencing DLTs (Dose Limiting Toxicity) | Safety Part: EMD 525797 500 mg + SoC | 0 | subjects | ||
| Safety Part: Number of Subjects Experiencing DLTs (Dose Limiting Toxicity) | Safety Part: EMD525797 750 mg + SoC | 0 | subjects | ||
| Safety Part: Number of Subjects Experiencing DLTs (Dose Limiting Toxicity) | Safety Part: EMD 525797 1000 mg +SoC | 0 | subjects | ||
| Randomized Part: Progression Free Survival (PFS) | Standard of Care (SoC) | 5.6 | 95% Confidence Interval 4.2 to 6.9 | months | |
| Randomized Part: Progression Free Survival (PFS) | EMD 525797 500 mg + SoC | 5.4 | 95% Confidence Interval 4.1 to 6.0 | months | |
| Randomized Part: Progression Free Survival (PFS) | EMD 525797 1000 mg + SoC | 5.6 | 95% Confidence Interval 4.1 to 6.9 | months | |
| Overall Survival (OS) Time | Standard of Care (SoC) | 11.6 | 95% Confidence Interval 9.8 to 15.7 | months | |
| Overall Survival (OS) Time | EMD 525797 500 mg + SoC | 15.0 | 95% Confidence Interval 10.9 to 19.2 | months | |
| Overall Survival (OS) Time | EMD 525797 1000 mg + SoC | 14.4 | 95% Confidence Interval 9.8 to 19.3 | months | |
| Time to Progression (TTP) | Standard of Care (SoC) | 5.8 | 95% Confidence Interval 4.4 to 7.2 | months | |
| Time to Progression (TTP) | EMD 525797 500 mg + SoC | 5.6 | 95% Confidence Interval 4.2 to 8.3 | months | |
| Time to Progression (TTP) | EMD 525797 1000 mg + SoC | 6.5 | 95% Confidence Interval 4.2 to 7.1 | months | |
| Number of Subjects With Tumor Response | Standard of Care (SoC) | CR | 2 | Subjects | |
| Number of Subjects With Tumor Response | EMD 525797 500 mg + SoC | CR | 1 | Subjects | |
| Number of Subjects With Tumor Response | EMD 525797 1000 mg + SoC | CR | 0 | Subjects | |
| Number of Subjects With Tumor Response | Standard of Care (SoC) | PR | 17 | Subjects | |
| Number of Subjects With Tumor Response | EMD 525797 500 mg + SoC | PR | 19 | Subjects | |
| Number of Subjects With Tumor Response | EMD 525797 1000 mg + SoC | PR | 18 | Subjects | |
| Time to Treatment Failure (TTF) | Standard of Care (SoC) | 5.2 | 95% Confidence Interval 4.4 to 6.2 | months |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT01008475/results